Researchers report possible therapeutic approach to fatty liver disease

February 15, 2016 by Christopher Packham, Medical Xpress report
3D-illustration of a human liver with blood vessels (red and blue) and bile duct (green) Source: Prof. Dr. Hans-Peter Meinzer, Deutsches Krebsforschungszentrum

(Medical Xpress)—Steatosis is a condition in which the body fails to properly synthesize or eliminate triglyceride fat, causing abnormal retention of lipids inside cells. Steatohepatitis, then, is liver disease characterized by inflammation and fat accumulation. The condition is typically seen in alcoholics, but it is often observed in people with diabetes and obesity. Ultimately, steatohepatits can progress to life-threatening cirrhosis.

Given the exponential rise of diabetes in developed countries, steatosis and steatohepatitis are subjects of tremendous interest to medical researchers. A new study, published in the Proceedings of the National Academy of Sciences, reports that treatment with fibroblast growth factor 1 (FGF1) is an important factor in adipose remodeling processes—mice deficient in FGF1 displayed a severe diabetic phenotype and increased inflammation and fibrosis in fatty tissues.

FGF1 is a protein encoded by the FGF1 gene. It encourages cell division and expresses a number of potent cell survival traits; this family of proteins is involved in a great number of functions including cell growth, embryonic development and tissue repair. In the current study, the researchers studied two different lines of mice: leptin-deficient mice, which develop steatosis through excessive eating; and mice with a dietary choline deficiency, which develop steatosis as a result of a defect in the way fat is broken down in the liver.

They found that FGF1 had dramatic antisteatotic effects in the leptin-deficient mice. Additionally, in these mice, FGF1 suppressed liver inflammation—hepatic steatosis can often develop into dangerous steatohepatitis characterized by serious inflammation. However, the antisteatotic effects observed in these mice were completely absent in the choline-deficient mice.

Choline deficiency causes steatosis in the absence of metabolic disease such as diabetes or obesity; the researchers conclude that the antisteatotic effects of FGF1 are dependent on catabolic pathways that are defective in the choline-deficient mice. The differences between the lines were also indicated by the zonal distribution of lipids in the animals' livers; lipid zoning is an important activity for segregating different metabolic pathways in the liver.

The study also concludes that FGF1 suppresses liver inflammation completely independently of its effects on fatty . "Our results show that rFGF1 effectively suppresses hepatic inflammation both in [leptin-deficient] mice and choline-deficient , as indicated by significant reductions in the expression of… proinflammatory M1 markers," the authors write.

And although the researchers thought there was potential for the treatment to produce such adverse effects as fibrosis and proliferation, these were not observed.

These results are important because no pharmacological treatments have been approved for steatohepatitis, and there are drawbacks to the existing approaches of insulin sensitizers and antioxidative treatments. By contrast, the study findings conclude that FGF1 improved hyperglycemia, insulin sensitivity and steatosis symptoms in the , though not the choline deficient line. "Our findings indicate that, in addition to its potent glucose-lowering and insulin-sensitizing effects, rFGF1 could be therapeutically effective in the treatment of non-alcoholic ," the authors write.

Explore further: Researchers discover a new target for the treatment of fatty liver disease

More information: Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease. PNAS 2016 ; published ahead of print February 8, 2016, DOI: 10.1073/pnas.1525093113

Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder and is strongly associated with obesity and type 2 diabetes. Currently, there is no approved pharmacological treatment for this disease, but improvement of insulin resistance using peroxisome proliferator-activated receptor-γ (PPARγ) agonists, such as thiazolidinediones (TZDs), has been shown to reduce steatosis and steatohepatitis effectively and to improve liver function in patients with obesity-related NAFLD. However, this approach is limited by adverse effects of TZDs. Recently, we have identified fibroblast growth factor 1 (FGF1) as a target of nuclear receptor PPARγ in visceral adipose tissue and as a critical factor in adipose remodeling. Because FGF1 is situated downstream of PPARγ, it is likely that therapeutic targeting of the FGF1 pathway will eliminate some of the serious adverse effects associated with TZDs. Here we show that pharmacological administration of recombinant FGF1 (rFGF1) effectively improves hepatic inflammation and damage in leptin-deficient ob/ob mice and in choline-deficient mice, two etiologically different models of NAFLD. Hepatic steatosis was effectively reduced only in ob/ob mice, suggesting that rFGF1 stimulates hepatic lipid catabolism. Potentially adverse effects such as fibrosis or proliferation were not observed in these models. Because the anti-inflammatory effects were observed in both the presence and absence of the antisteatotic effects, our findings further suggest that the anti-inflammatory property of rFGF1 is independent of its effect on lipid catabolism. Our current findings indicate that, in addition to its potent glucose-lowering and insulin-sensitizing effects, rFGF1 could be therapeutically effective in the treatment of NAFLD.

Related Stories

Researchers discover a new target for the treatment of fatty liver disease

February 3, 2016
Two proteins, p38 gamma and p38 delta, control the accumulation of fat in the liver, a process linked to the development of insulin resistance and diabetes, which are common outcomes of obesity. These findings are presented ...

A G-Protein-Coupled Receptor may be a drug target for nonalcoholic fatty liver disease

January 11, 2016
New research published in the January 2016 issue of The FASEB Journal suggests that the G-protein-coupled receptor 119 (GPR119) could be a viable treatment target for nonalcoholic fatty liver disease. This receptor has already ...

Fatty liver disease and scarring have strong genetic component

October 1, 2015
Researchers at the University of California, San Diego School of Medicine say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as ...

One injection stops type 2 diabetes in its tracks in mice without side effects

July 16, 2014
In mice with diet-induced diabetes—the equivalent of type 2 diabetes in humans—a single injection of the protein FGF1 is enough to restore blood sugar levels to a healthy range for more than two days. The discovery by ...

Short-chain fatty acids in diet stimulate fat utilization

March 6, 2015
(HealthDay)—Short-chain fatty acids (SCFAs), the main products of dietary fiber fermentation, induce a peroxisome proliferator-activated receptor (PPAR) γ-dependent switch from lipid synthesis to lipid utilization, according ...

New source of liver disease in obesity caused by saturated fat, but not unsaturated fat

January 19, 2016
In results published on October 19, 2015 in the Journal of Lipid Research, a team of translational scientists at the Medical University of South Carolina (MUSC) report a new reason why non-alcoholic steatohepatitis (NASH) ...

Recommended for you

Breakthrough could lead to better drugs to tackle diabetes and obesity

February 22, 2018
Breakthrough research at Monash University has shown how different areas of major diabetes and obesity drug targets can be 'activated', guiding future drug development and better treatment of diseases.

Iron triggers dangerous infection in lung transplant patients, study finds

February 21, 2018
Researchers at the Stanford University School of Medicine have identified elevated tissue iron as a risk factor for life-threatening fungal infections in lung transplant recipients.

Neuroimaging reveals lasting brain deficits in iron-deficient piglets

February 21, 2018
Iron deficiency in the first four weeks of a piglet's life - equivalent to roughly four months in a human infant - impairs the development of key brain structures, scientists report. The abnormalities remain even after weeks ...

Scientists in Germany improve malaria drug production

February 21, 2018
Scientists in Germany who developed a new way to make a key malaria drug several years ago said Wednesday they have come up with a technique to make the process even more efficient, which should increase global access and ...

Products derived from plants offer potential as dual-targeting agents for experimental cerebral malaria

February 21, 2018
Malaria, a life-threatening disease usually caused when parasites from the Plasmodium family enter the bloodstream of a person bitten by a parasite-carrying mosquito, is a severe health threat globally, with 200 to 300 million ...

Early results from clinical trials not all they're cracked up to be, shows new research

February 21, 2018
When people are suffering from a chronic medical condition, they may place their hope on treatments in clinical trials that show early positive results. However, these results may be grossly exaggerated in more than 1 in ...

3 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

SkyAbove
1 / 5 (2) Feb 15, 2016
My wife and I are vitamin junkies. We've taken choline and DMAE supplements for thirty years. Our visceral fat measurements from medical tests are always excellent. Now we know why thanks to this discovery/article.
big_hairy_jimbo
not rated yet Feb 15, 2016
@SkyAbove I can't find any scientific evidence to back DMAE supplements. In fact I'd go as far to say that anything advertised by Dr.Oz is a sham. Dr.Oz has regularly promoted products which are very dubious, some have even caused Liver Damage. He has also been called in front of congress to explain his financial links with the products he advertises as life extenders or fat loss products.

http://edition.cn...s-dr-oz/

Also another "supplement" Garcinia cambogia, is also known to cause Liver failure. The problem being many Garcina cambogia products also contain Green-Tea and various other "boosters".

Please don't promote supplements that have no scientific evidence to back the claim you have made.
drj27
not rated yet Feb 15, 2016
Stop eating high fructose corn syrup it's that simple.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.